BioSpace News Archive

Aditxt, Inc. today announces that the Company and its subsidiary, Pearsanta, Inc. (“Pearsanta”), has acquired MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early disease and cancer detection platform.

Outset Medical, Inc. today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, and provided 2024 financial guidance.

Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical-stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration.

Merit Medical Systems, Inc., a leading global manufacturer and marketer of healthcare technology, announced projected preliminary unaudited revenue in the range of approximately $1.255 to $1.259 billion for the year ended December 31, 2023, a projected increase of approximately 9.0% to 9.4% compared to revenue reported for the year ended December 31, 2022.

Rivermark Medical announced today the successful completion of its RAPID-UR study, an extended indication study that evaluated the use of the Company’s FloStent System in patients suffering urinary retention due to BPH.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2023.

Solid Biosciences Inc. announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement, which is expected to close on or about January 11, 2024, subject to the satisfaction of customary closing conditions.

Aurora Spine Corporation, a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, announced that it will be attending the J.P. Morgan Healthcare Conference in San Francisco, CA the week of January 8-11, 2024.

XOMA Corporation, the biotech royalty aggregator, announced the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) announced today that its SGX945 (dusquetide) development program for the treatment of oral lesions of Behçet’s Disease has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA).